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Possible mechanism of impaired calcium and vitamin D
metabolism in nephrotic rats
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Division of Nephrology, Department of Medicine, Juntendo University School of Medicine, Tokyo, Japan
Possible mechanism of impaired calcium and vitamin D metabolism in
nephrotic rats. Patients who have nephrotic syndrome and normal renal
function are hypocalcemic in spite of the elevated levels of serum
parathyroid hormone (PTH) caused by a low serum concentration of
1 ,25-dihydroxyvitamin DEl ,25(OH)2D], presumably because of its loss
in urine. However, it has not been established whether the conversion
of 25-hydroxyvitamin D[25(OH)D] into 1 ,25(OH)2D is impaired in the
kidney. In this study, we examined the serum levels of vitamin D
metabolites, and kinetics of renal 25(OH)D-1-hydroxylase activity in
vitro, and nephrogenous cyclic AMP excretion in response to exoge-
nous PTH administration in puromycin aminonucleoside-induced neph-
rosis in rats. Plasma ionized calcium and the serum levels of vitamin D
metabolites were lower, and conversely, the serum PTH level was
higher, in nephrotic rats than in controls. Serum I ,25(OH)2D levels
were higher in 25(OH)D3-treated nephrotic rats than in untreated
nephrotic rats, indicating that the low l,25(OH)2D level in nephrotic
rats is partially due to the low concentration of 25(OH)D. Although
PTH levels were higher in nephrotic rats than in control rats, the Vmax
of renal 25(OH)D-l-hydroxylase and nephrogenous adenosine 3,5'-
monophospate (cyclic AMP) excretion in response to exogenous PTH
were significantly lower in nephrotic animals than in controls. These
results suggest that abnormalities in calcium and vitamin D metabolism
in nephrotic rats are partially attributable to impaired proximal tubular
function.
Nephrotic syndrome is defined on the basis of heavy protein-
uria accompanied by hypoalbuminemia, hyperlipidemia and
edema. Patients who have nephrotic syndrome and normal
renal function frequently have abnormalities in calcium metab-
olism that manifest as hypocalcemia, hypocalciuria and reduced
intestinal absorption of calcium [1, 2]. Although hypocalcemia
was initially attributed to hypoalbuminemia, many patients with
nephrotic syndrome have low levels of ionized calcium [1—5].
Additional studies have revealed the presence of osteomalacia,
hyperparathyroidism and blunted calcemic response to PTH [1,
6]. Studies of vitamin D metabolites in nephrotic patients have
demonstrated low levels of serum 25(OH)D [1—4] and reduced
levels of serum 1 ,25(OH)2D [5, 7—9] and 24,25-dihydroxyvita-
mm D [6, 9—11]. Further studies on vitamin D metabolites in the
urine have shown large urinary loss of these metabolites to-
gether with the vitamin D binding protein [9, 121. Chan et al [13]
have also reported that low levels of serum vitamin D metabo-
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lites are associated with massive urinary loss of injected 3H-
labelled vitamin D3. However, the mechanism of abnormal
regulation of calcium and vitamin D metabolism in nephrotic
syndrome remains unclear. Some studies have suggested that
the low concentration of serum 1 ,25(OH)2D in nephrotic syn-
drome may be partially due to a deficient substrate, 25(OH)D
[6, 7], and the conversion of 25(OH)D into 1,25(OH)2D may be
impaired in the kidney [14]. Since these mechanisms have not
yet been examined, we undertook the present studies on serum
levels of vitamin D metabolites, kinetics of renal 25(OH)D-l-
hydroxylase activity in vitro and nephrogenous adenosine 3',5'-
monophosphate (cyclic AMP) excretion in response to exoge-
nous PTH administration in rats made nephrotic by puromycin
aminonucleoside (PAN).
Methods
Animals
Male Sprague-Dawley rats (Japan Charles River Laborato-
ries, Kanagawa, Japan) weighing 230 to 250 g were used. All
rats were raised on a commercial chow (Funabasi Farms Co.
Ltd., Chiba, Japan) containing 1.17% calcium, 0.75% phospho-
rus, 200 IU/100 g vitamin D3, 24.6% protein, 5.6% fat and 358
kcal/100 g, and were pair-fed.
Experimental protocols
Eighteen rats were subcutaneously injected daily with 0.3 ml
of a saline solution containing 0.5% PAN per 100 g of body
weight for 12 days (nephrotic group) [15]. Twelve rats were
injected with the same amount of saline (control group), Six
nephrotic rats were given intraperitoneal injection of 100 inter-
national units (IU) of 25(OH)D3 in 0.5 ml of propylene glycol
daily for the last three days (25(OH)D3-treated nephrotic
group). Six rats of the nephrotic group and six of the control
group received intraperitoneal injection of 10 IU of human
PTH(l-34) in 0.2 ml of saline one hour prior to sacrifice, and
urine samples for one hour before and after PTH injection were
collected for the measurement of nephrogenous cyclic AMP.
Rats were anesthetized with ether and completely exsan-
guinated from the aorta with a syringe on the thirteenth day.
The animals were then perfused with 100 ml of calcium and
magnesium free, phosphate-buffered saline. The kidneys were
removed for the measurement of renal 25(OH)D-l-hydroxylase
activity. Serum samples were collected for the measurement of
vitamin D metabolites [25(OH)D, 1 ,25(OH)2D], mid-molecule
PTH and cyclic AMP.
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Tabie 1. Biochemical data in control, nephrotic and 25(OH)D3-treated nephrotic rats on the 13th day
Group
Ca P
Mg
inEqiliter
Creatinine
mg/dl
Urine protein
mg124 hring/di
Control (N = 6)
Nephrotic (N = 6)
Nephrotic +25(OH)D1(N =6)
9,97
4.49
5.26
0.40
0.28a
0.55a
7.48 0,55
7.76 0.85
7.74 0.60
2.20 0.20
2.20 0.15
2.23 0.17
0.79 0.20
0.85 0.20
0.83 0.36
7.1 1.1
215.2 39,3a
206.0 3o.I
Values are expressed as means SCM.
a Significantly different from the control value (P < 0.01).
Measurement of renal 25-hydroxyvita,nin D-1 -hydroxvlase
activity
Renal 25(OH)vitamin D-1-hydroxylase was measured by the
method of Horiuchi et al [16]. After perfusion by phosphate-
buffered saline, the kidneys were removed and placed in
ice-cold 15 msi Tris-acetate buffer (pH 7.4) containing 0.19 M
sucrose, 2 m magnesium acetate and 25 m sodium succinate.
A 10% (wt/vol) homogenate was prepared in the Tris-acetate
buffer. Graded amounts of 25(OH)[3H}D5 dissolved in ethanol
were added to 3 ml of the homogenates. Then, the homogenates
were incubated at 37°C for 20 minutes. The reaction was
stopped by adding 10 ml of methanol/chloroform (2/1, vol/vol).
Extraction was performed by the method of Bligh and Dyer
[17]. The lipid extract was mixed with authentic l,25(OH)2D3
and applied to a column for straight phase, reverse phase
high-performance liquid chromatography (HPLC). A thirty
second fraction was collected and radioactivity was counted
with a liquid scintillation counter (model LS3801, Beckman,
California, USA). The Km and Vmax of the enzyme activity
were analyzed by Lineweaver-Burk plot. Six rats were used for
each amount of 25(OH)D3 and three series were carried out. We
used 72 rats in one series.
Authentic vitamin D metabolites were generously provided
by Chugai Pharmaceutical Co. Ltd., (Tokyo, Japan) and syn-
thetic human PTH(1-34) was provided by Toyo Jozo Co.,
(Sizuoka, Japan). Radioactive vitamin D metabolites were
purchased from Amersham Japan Co., (Tokyo, Japan).
Effect of PAN on cyclic AMP response to PTH in rat kidney
homogenate
Male Sprague-Dawley rats weighing 230 to 250 g were killed
by decapitation. The kidney receptor was prepared according to
the Marx and Aurbach [18]. Rat kidney tissues were homoge-
nated in 5 volumes (wt/vol) of 10 mrvi Tris-HC1 buffer, pH 7.5,
containing 1 mM EDTA and 10% dimethylsulfoxide. The ho-
mogenate was centrifuged for 30 seconds at 2200 g, and the
supernatant was recentrifuged for 20 minutes at 2200 g. The
second pellet, containing crude renal membrane, was sus-
pended in 10 mrs Tns-HC1 buffer, pH 7.5, and stored at —80°C.
Two hundred micrograms of crude renal membrane and
varying amounts of human PTH( 1-34) were incubated with or
without 125 g PAN in 200 d 3 mts ATP, 6 mrvi MgCI1, 0.5 mM
1-methyl-3-isobutylxanthine, 10 msi creatine phosphate, 30
U/mI phosphocreatinekinase, 1 mglml bovine serum albumin,
and 10 m Tris-HC1, pH 7.4, at 37°C for 20 minutes. To
terminate the reaction, crude membrane was heated at 95°C for
three minutes. Cyclic AMP was measured with Yamasa cyclic
AMP assay kits (Yamasa Co. Ltd., Chiba, Japan).
Determination of biochemical data
Serum concentration of calcium and magnesium was deter-
mined by an atomic absorption spectrophotometer (model
RA-1, Hitachi, Tokyo, Japan). Serum ionized calcium was
measured with a NOVA electrode (NOVA-6, NOVA Co.,
Massachusetts, USA). Serum phosphorus was measured ac-
cording to the procedure of Fiske and Subbarow [19]. Serum
and urinary creatinine were determined with a Technicon
autoanalyzer (Technicon Instrument Corp., Tarrytown, New
York, USA). Urinary protein was determined by Bio-Rad
protein assay with bovine serum albumin as the standard.
Serum mid-molecule PTH was measured with rat PTH-MM
assay kits that detect the 44-68 portion of rat PTH (INC STAR
Inc., Minnesota, USA). In this assay, the lower limit of
detection was 16 pmol/liter, the intraassay coefficient of varia-
tion was 5.4% and the interassay coefficient was 9.4%. Neph-
rogenous cyclic AMP was measured using Yamasa cyclic AMP
assay kits (Yamasa Co. Ltd., Chiba, Japan). Serum concentra-
tions of 25(OH)D and 1 ,25(OH)2D were determined by radio-
immunoassay and competitive protein binding assay as de-
scribed previously [20]. The lipid extract from serum was
chromatographed on a Sephadex LH-20 column. The fraction
that contained both 25(OH)D and 24,25(OH)2D and the subse-
quent fraction with 1 ,25(OH)2D were collected separately.
Each fraction was evaporated and applied to a column for
straight phase, reverse phase high performance liquid chroma-
tography (HPLC). In this assay, the lower limit of detection of
25(OH)D was 0.5 ng/ml, the intraassay coefficient of variations
was 7.1%, and the interassay coefficient 9.5%. The lower limits
of detection of 1,25(OH)2D was 2 pg/ml, the intraassay coeffi-
cient of variations was 10.1%, and the interassay coefficient was
10,5%.
Statistics
All results comparing experimental groups are expressed as
mean SEM. Statistical analyses were carried out with Stu-
dent's f-test.
Results
Serum biochemical data obtained on the thirteenth day in
control, nephrotic and 25(OH)D3-treated nephrotic rats are
shown in Table 1. The nephrotic and 25(OH)D3-treated ne-
phrotic rats had heavy proteinuria and normal serum creatinine
levels. Hypocalcemia was found in nephrotic and 25(OH)D3-
treated nephrotic rats, but there were no significant differences
in the serum concentrations of phosphorus and magnesium
among the three groups. There was no significant difference in
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serum biochemical data between the nephrotic rats and
25(OH)D3-treated nephrotic rats.
The concentration of ionized calcium in nephrotic rats was
significantly lower than that in control rats (Fig. I). The
concentration of ionized calcium in 25(OH)D3-treated nephrotic
rats was significantly lower than that in controls, but signifi-
cantly higher than that in untreated nephrotics.
The serum levels of PTH in nephrotic and 25(OH)D3-treated
nephrotic rats were significantly higher than those in control
rats (Fig. 2). However, there was no significant difference in
serum PTH levels between nephrotic rats and 25(OH)D3-
treated nephrotic rats.
The serum concentration of 25(OH)D in 25(OH)D3-treated
nephrotic rats was significantly higher than that in control rats
(Fig. 3). However, serum 25(OH)D in nephrotic rats was not
detectable by our assay system (less than 0.5 ng/ml).
Figure 4 shows the serum concentration of 1 ,25(OH)2D in
three groups. The serum 1 ,25(OH)2D level in nephrotic rats was
significantly lower than that in control rats. The serum concen-
tration of 1 ,25(OH)2D in 25(OH)D3-treated nephrotic rats was
also significantly lower than that in control rats, but signifi-
cantly higher than that in untreated nephrotic rats.
The kinetics of renal 25(OH)D- l-hydroxylase in the control
and nephrotic groups are presented in Table 2. Despite the
elevated serum PTH level, the Vmax of renal 25(OH)D-l-
hydroxylase in nephrotic rats was significantly lower than that
Fig. 2. Serum PTH levels in control (0, N = 6), nephrotic (LI, N = 6),
and 25(OH)D3-treated nephrotic (, N = 6) rats. The values are
expressed as mean SEM.
in control rats, whereas the Km of renal 25(OH)D-l-hydroxy-
lase in nephrotic rats was not significantly different from that in
control rats.
The response of nephrogenous cyclic AMP excretion to
human PTH(l-34) in control and nephrotic rats is shown in
Table 3. The basal level of nephrogenous cyclic AMP excretion
in nephrotic rats was significantly lower than that in control rats
despite the elevation in serum PTH. After the injection of PTH,
nephrogenous cyclic AMP excretion showed only a 1.5-fold
increase in nephrotic rats, compared with a 12-fold increase in
control rats (P < 0.001).
The cyclic AMP response to PTH in kidney homogenate is
presented in Table 4. By adding varying amounts of human
PTH (10 M — l0M) to kidney homogenate, PTH-stimulated
cyclic AMP production did not differ significantly in the pres-
ence or absence of PAN in the incubation medium.
Discussion
Although serum phosphorus, magnesium and creatinine lev-
els were not significantly different between PAN nephrotic rats
and control rats, the serum levels of calcium, ionized calcium,
25(OH)D, and l,25(OH)2D in nephrotic rats were significantly
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Fig. 3. Serum 25(OH)D levels in control (LII N = 6), and 25(OH,1D3-
treated nephrotic (, N = 6) rats. Serum 25(OH)D in nephrotic rats
was not detectable. The values are expressed as mean SEM.
lower in nephrotic rats than in controls. Nephrotic rats also had
an elevated level of serum PTH. These abnormalities in param-
eters of calcium metabolism in PAN nephrotic rats were similar
to those in human nephrotic syndrome [1, 2, 4—6].
A number of studies have examined calcium metabolism in
nephrotic syndrome. Sato, Gray and Lemann [21] demon-
strated increased urinary excretion of 25(OH)D, decreased
serum vitamin D binding protein (DBP), and a good correlation
between urinary 25(OH)D and urinary protein in patients with
nephrotic syndrome. Urinary excretion of DBP also has been
demonstrated in nephrotic patients [12, 22]. In the studies of
Barragry et al [121 in nephrotic patients and Chan et al [13] in
nephrotic rats, administration of 3H-labeled cholecalciferol
resulted in the rapid appearance of radioactive vitamin D
metabolites in urine. Furthermore, Lambert et al [9] demon-
strated an increased urinary excretion of 25(OH)D and
l,25(OH)2D in nephrotic patients. It has been suggested that the
reduced serum levels of 25(OH)D and 1 ,25(OH)2D in patients
with nephrotic syndrome are caused by increased loss of these
metabolites with DBP in urine.
However, the results of these investigations do not explain all
the abnormalities in calcium and vitamin D metabolism in
patients with nephrotic syndrome. Kubota et al [14] have
reported that in nephrotic patients the serum level of 25(OH)D
rose promptly with successful treatment and clinical remission,
and showed a good correlation with serum albumin concentra-
tion, whereas the serum level of 1 ,25(OH)2D remained low even
after remission, which showed no correlation with serum albu-
min concentration. One explanation offered was that impaired
renal synthesis of 1 ,25(OH)2D may be involved in the patho-
physiology of nephrotic syndrome. Auwerx et al [7] demon-
Fig. 4. Serum I ,25(OH12D levels in control (LII, N = 6), nephrotic (D,
N = 6), and 25(OH)D3-treated nephrotic (, N = 6). The values are
expressed as mean SaM.
Table 2. Kinetics of renal 25(OH)D-1-hydroxylase in control and
nephrotic rats
Group
Vmax
ng/300 ing tissue/20 mm
Apparent Km
x l0 M
Control
(N =3) 56.9 4.6 1,9 0.7
Nephrotic(N=3) 28.5 2.2a 1.0 0.4
Values are expressed as means SEM.
a Significantly different from the control value (P < 0.01)
strated decreased free 1 ,25(OH)2D in nephrotic patients and
implicated a decreased amount of substrate [25(OH)D] or
deficient renal 25(OI-OD-l-hydroxylase activity.
In the present study, the serum l,25(OH)2D level in
25(OH)D3-treated nephrotic rats was significantly higher than
that in nephrotic rats. The administration of sufficient substrate,
25(OH)D3, to nephrotic rats resulted in a significant increase in
the serum concentration of I ,25(OH)2D, suggesting that the low
serum 1 ,25(OH)2D level in nephrotic rats is at least partly due to
the low concentration of substrate. This explanation is compat-
ible with a study showing that the treatment with 25(OH)D3
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Table 3. Nephrogenous cyclic AMP in control and nephrotic rats
Before After
Group PTH injection PTH injection
Control
(N = 6) 2303.7 266.4 28809.1 4158.2
Nephrotic
(N = 6) 282.2 32.6a 413.0 78.5a
Values are expressed as means SEM (nmol/l00 ml GF).
a Significantly different from the control value (P < 0.01)
Table 4. Effect of puromycin aminonucleoside on cyclic AMP
production by PTH stimulation in rat kidney homogenate
PTH PAN(+) PAN(-)
(—) 45±4 41±3
l0— 106 11 112 8l0 203 18 200 21l0- 452 38 448 41
Values are expressed as means SEM (pmol cyclic AMP/200 tg
protein/20 mm). No significant difference between PAN(+) and
PAN(-).
increased the serum concentration of I ,25(OH)2D in patients
with nephrotic syndrome without renal failure [8].
However, in the present study, the serum concentration of
1 ,25(OH)2D in 25(OH)D3-treated nephrotic rats remained still
lower than that observed in control rats. This suggests that
deficient renal 25(OH)D-l-hydroxylase activity exists in ne-
phrotic syndrome. The kinetic study of renal 25(OH)D-l-hy-
droxylase revealed a significantly lower Vmax in nephrotic rats
than in controls. Furthermore, the basal level of nephrogenous
cyclic AMP excretion in nephrotic rats was also significantly
lower than that in controls. The response of nephrogenous
cyclic AMP to a pharmacological dose of human PTH( 1-34) was
also impaired in nephrotic rats.
No significant differences in the renal cell response to PTH in
term of cyclic AMP synthesis were noted in the presence or
absence of PAN. Diamond and Anderson [23] also have dem-
onstrated that PAN does not affect rat kidney epithelium in
vitro. Therefore, it is unlikely that PAN has a direct effect on
renal cells. The decreased max of 25(OH)D-1-hydroxylase and
the blunted response of nephrogenous cyclic AMP to PTH may
reflect another mechanism for abnormalities in calcium and
vitamin D metabolism in nephrotic rats. The cause of the
decreased max of the enzyme and diminished cyclic AMP
response to PTH may be impaired proximal tubular function by
massive protein reabsorption in the nephrotic states.
These results suggest that abnormalities in calcium and
vitamin D metabolism in patients with nephrotic syndrome are
attributable to impaired proximal tubular function as well as
urinary loss of vitamin D metabolites. The vitamin D-deficient
state contributes to bone resistance to PTH, and the defective
response to PTH may enhance hypocalcemia in patients with
nephrotic syndrome.
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